The biggest role of portable instant detection products is to achieve the dispersion of medical care, reduce the burden on medical staff, and achieve restrictions on disease screening, thus opening up a large market. 1 Advantages of rHEALTH technology Developers refer to the technology in the above-mentioned news, called rHEALTH technology, which can be used to detect cell counts, HIV infection, vitamin D levels, various proteins in the body, etc., and the technology needs to collect less blood, so it has both Portable, versatile, and integrated. 2 Portable testing products using trace blood Based on rHEALTH technology, developers are working on three products based on different needs: rHEALTH One for translational research, rHEALTH X for clinical applications, and rHEALTH X1 for end consumers. In addition to the rHEALTH series, a number of portable inspection products have been developed that have evolved beyond the traditional wearables category. For example, the portable microchip developed by Stanford University School of Medicine can be used to quickly detect high-risk type 1 diabetes patients while avoiding the use of traditional radioactivity, and to distinguish between type I and type II diabetes. Similar to the rHEALTH series, the use of microchips has a small amount of blood. In the field of rapid detection of type 2 diabetes, Roche and Siemens have developed a wide range of portable testing products. 3 The market for portable inspection products In addition to blood testing and wearable devices, the development of portable rapid detection kits for urine, saliva or other body fluids is in full swing and can be directly passed through colorimetry through integration with third-party applications (APP) such as the Colorimetrix app. To a certain extent, the functions that can be realized by high-sensitivity spectrophotometers can be realized, which greatly promotes the rapid development of mobile medical care . The biggest role of portable instant detection products is to achieve the dispersion of medical care, reduce the burden on medical staff, and achieve restrictions on disease screening, thus opening up a large market. If wearables are still in the early stages of development, portable blood glucose meters and the like have fully demonstrated the huge market prospects. For example, Cepheid's multi-drug resistant Staphylococcus aureus (MRSA) and drug-resistant M. tuberculosis (MTB) in-hospital infection testing products have almost zero sales at the time of launch, but have now expanded to hundreds of millions of dollars. In fact, whether it is the detection of infectious diseases such as AIDS, tuberculosis and dysentery, or the detection of common physiological indicators, it is possible to achieve this through rapid detection kits and portable detection equipment (most commonly using the colorimetric of APP). In addition to disease detection, in the diagnosis and environmental monitoring of the livestock industry, product development and market expansion have started. 4 Cross-competition pattern of many types of enterprises For this reason, even traditional pharmaceutical companies (such as Bayer) are looking for opportunities to expand into the medical device market. In addition, as future portable detection devices increasingly rely on analog and mixed-signal processing technologies, many semiconductor companies, software companies and Internet companies are also joining the competition in this field, forming a cross-sectional expansion pattern. For example, micro-magnetic nanoparticles developed by Google X Labs can be used to detect and monitor a user's health status for disease screening. 5 Technological breakthroughs behind miniaturization From the perspective of semiconductor technology, the development of portable products such as micro-magnetic nanoparticles depends on the miniaturization of products, which in turn depends on high-precision, highly integrated signal chain products and power management and radio frequency product development for portable applications. . At the same time, the miniaturization of sensor volume in the future may also mean a simultaneous reduction in cost. When the cost is reduced to a sufficiently low level, perhaps the new sensor will be disposable and can be developed and applied in all categories of portable products. 6 From common biochemical diagnostics to molecular diagnostics From the perspective of biological detection methods, the development of portable real-time detection products has gradually expanded from traditional biochemical methods to molecular diagnostic technology. At the same time that Life Technologies, GE Healthcare and Promega develop sequencing products, the development of portable sequencers has also entered the field of research of many researchers. For example, researchers at the University of Otago in New Zealand have developed the portable DNA sequencer Freedom 4, which weighs as much as a laptop and can be used for medical tests such as viral infections, detection of livestock diseases, and monitoring of environmental microorganisms. The detected data can be transmitted in real time through a smartphone and analyzed by the application. For another example, Nippon Electric Co., Ltd. (NEC) has also developed a portable DNA analyzer (P-DNA Analyzer) for forensic science, which can be used for the analysis of mucus and blood samples without the need to transport samples to the laboratory. Rapid identification of DNA within one hour. 7 The era of data analysis From the perspective of information technology, the development of portable detection equipment will also mean a massive increase in data size. In the future, the number of hardware-only sensors will probably reach trillions, and the amount of data will far exceed the size of what is considered "big data" today. At the same time, the data types will be greatly expanded, and the fusion analysis application will enrich people's knowledge. For example, in the medical field alone, the fusion of multiple types of data such as cardiac data (such as heart rate, pulse rate, respiratory rate, body temperature, heat consumption, etc.) and molecular data may lead a new era of health research. With the expansion of data acquisition, analysis and application, whether big data analysis can partially replace clinical trials may become a major issue for future R&D, regulation and consumer thinking. Anesthesia Medical Co., Ltd. , https://www.medicaldiverse.com